A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or With Pegylated Endostatin for Advanced Non-small Cell Lung Cancer
A randomized phase 2 study, involving patients with advanced non-small-cell lung cancer who
had not previously received chemotherapy, compared paclitaxel and carboplatin Plus placebo
with paclitaxel and carboplatin plus PEGylated endostatin, with PEGylated endostatin at a
dose of 10 mg/m2 intravenously every weeks.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Progression free survival
6 weeks
No
Yan Sun, MD
Principal Investigator
cancer hospital, Chinese academy of medical science
China: Food and Drug Administration
M2ES2011-1
NCT01527864
May 2011
April 2013
Name | Location |
---|